Quick Answer
Karyopharm Therapeutics Inc. reported Cash and Equivalents of $60.54 million for fiscal year 2025.
Karyopharm Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $60.54M | -3.1% |
| 2024 | $62.48M | +19.6% |
| 2023 | $52.23M | -61.4% |
| 2022 | $135.19M | -29.0% |
| 2021 | $190.46M | +121.7% |
| 2020 | $85.92M | -33.3% |
| 2019 | $128.86M | +9.2% |
| 2018 | $118.02M | +71.1% |
| 2017 | $69.00M | +38.9% |
| 2016 | $49.66M | -14.9% |
| 2015 | $58.36M | -61.3% |
| 2014 | $150.61M | -3.4% |
| 2013 | $155.97M | +39791.0% |
| 2012 | $391.0K | -94.0% |
| 2011 | $6.51M | +89.0% |
| 2010 | $3.44M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $37.67M | -48.3% | -2.7% |
| June 30, 2025 | $38.73M | -54.3% | -0.1% |
| March 31, 2025 | $38.78M | +26.6% | -37.9% |
| December 31, 2024 | $62.48M | +19.6% | -14.2% |
| September 30, 2024 | $72.83M | +66.8% | -14.1% |
| June 30, 2024 | $84.77M | +4.8% | +176.8% |
| March 31, 2024 | $30.63M | -63.6% | -41.4% |
| December 31, 2023 | $52.23M | -61.4% | +19.6% |
- Karyopharm Therapeutics Inc. showed a decrease of -3.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, Karyopharm Therapeutics Inc.’s cash and equivalents has grown by 1657.3% (from $3.44 million to $60.54 million).
- The most recent figure is from Karyopharm Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: